It is a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth factor 1 deficiency1 The acquisition of the treatment for this rare disease is an example of ESTEVE's commitment focused on growth opportunities in high unmet medical and patient needs. BARCELONA, Spain, April 1, 2025 /PRNewswire/ -- ESTEVE has signed a license and supply agreement with Eton Pharmaceuticals with global rights for Increlex®, except for USA.

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.The

Axsome Therapeutics said Tuesday that a Phase 3 trial for its narcolepsy drug Sunosi failed to meet its primary goal in major depressive disorder. The company was testing Sunosi in patients who had MDD with or without excessive daytime sleepiness — the hallmark symptom of narcolepsy. In a 346-patient study, Sunosi did not separate from placebo on a depression symptom rating scale called MADRS after six weeks by a statistically significant margin. Axsome’s stock price $AXSM slipped about 6% in

Program partner to develop GenAI solutions that seamlessly integrate with Veeva applications CHICAGO, April 1, 2025 /PRNewswire/ -- EVERSANA, a global provider of commercial services to the life sciences industry, today announced it has been named an official Veeva AI Partner, managed by Veeva Systems, a global leader in cloud software serving the life sciences industry. EVERSANA joins more than 20 organizations in the Veeva's AI Partner Program, which provides partners access to critical techno

AIRNA is focused on genetic variations that cause disease, plus using precision editing tech to tweak RNA into more healthy variations.\n AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 million series B fundraise.The round was led by Venrock Healthcare Capital Partners and Forbion Growth, AIRNA announced in an April 1 release. Forbion had previously led AIRNA’s $60 million financing in July 2024. Other investors i

Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S.DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the out-licensing of commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. (“Esteve”). “Esteve shares Eton’s dedication

DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia (IH). ALKS 2680 is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH – chronic, neurological disorders characterized by excessive d

124I-evuzamitide (AT-01) PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected or diagnosed with cardiac amyloidosis in ATTR, AL, and other rare types of systemic amyloidosis.124I-evuzamitide PET/CT demonstrated uptake in multiple organs with amyloid deposition utilizing cutoffs from automated quantification in patients with AL and ATTR amyloidosis.Phase 3 – REVEAL study with 124I-evuza

Compass Therapeutics said Tuesday that adding its bispecific antibody to chemotherapy significantly improved response rates compared to chemotherapy alone in a Phase 2/3 biliary tract cancer study. Not to be confused with psychedelics developer Compass Pathways, Compass Therapeutics is studying tovecimig, a bispecific antibody that targets two signaling pathways — DLL4 and VEGF-A. Both play key roles in helping tumors develop the network of vessels they rely on for nutrients and oxygen. The Phas

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatme